Home › Research › Lewy body dementia
Novel approaches for the treatment of frontotemporal dementia: is there hope for the future?
Madia Lozupone, Vittorio Dibello, Rodolfo Sardone, Fabio Castellana, Roberta Zupo, Luisa Lampignano, Ilaria Bortone, Giancarlo Sborgia et al.. Expert Review of Neurotherapeutics, 2025-08-13
Topic: Risk, prevention and care in population studies
Plain-language summary
INTRODUCTION: Frontotemporal dementia (FTD) refers to a group of neurodegenerative disorders characterized clinically by behavioral disturbances and pathologically by frontal and anterior temporal lobe neurodegeneration, resulting in brain atrophy. No disease-modifying therapy currently exists for FTD. Familial FTD is primarily caused by three major genetic mutations, extensively investigated during the preclinical phases. Compounds developed to date have been designed to target specific mutations. A shift to broader approaches targeting abnormal protein deposition must employ endpoints that are meaningful to genetic and sporadic FTD, despite the diversity of their symptoms. AREAS COVERED: The authors review the most recent pharmacological and non-pharmacological randomized clinical trials (RCTs), focusing on the molecules involved, mechanisms of action, and pharmacological testing. The present review article is based on multiple database searches (MEDLINE, EMBASE, Scopus, Ovid, and Google Scholar) on all the available literature up to the 1 May 2025. EXPERT OPINION: Ongoing RCTs aimed to evaluate new disease-modifying or symptomatic treatment for FTD and to determine whether therapeutic strategies should target specific genetic mutations or focus on common protein deposits in the brain. These studies are laying the groundwork for future innovations. This shift could enable the transition from treating genetic FTD to tackling sporadic cases as well.
What this study adds
Evidence grade: High
No disease-modifying therapy currently exists for frontotemporal dementia, and compounds developed so far have been designed to target specific genetic mutations. Ongoing randomized clinical trials are evaluating new disease-modifying or symptomatic treatments and whether strategies should target specific mutations or common protein deposits, but these are still laying groundwork for future innovations.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Lozupone, M., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., et al. (2025). Novel approaches for the treatment of frontotemporal dementia: is there hope for the future? Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2025.2546867
Vancouver
Lozupone M, Dibello V, Sardone R, Castellana F, Zupo R, Lampignano L, et al. Novel approaches for the treatment of frontotemporal dementia: is there hope for the future? Expert Review of Neurotherapeutics. 2025. doi:10.1080/14737175.2025.2546867. PMID: 40804782.
BibTeX
@article{lozupone2025-40804782,
author = {Lozupone, Madia and Dibello, Vittorio and Sardone, Rodolfo and Castellana, Fabio and Zupo, Roberta and Lampignano, Luisa and Bortone, Ilaria and Sborgia, Giancarlo and others},
title = {{Novel approaches for the treatment of frontotemporal dementia: is there hope for the future?}},
journal = {Expert Review of Neurotherapeutics},
year = {2025},
doi = {10.1080/14737175.2025.2546867},
pmid = {40804782},
url = {https://doi.org/10.1080/14737175.2025.2546867}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- AREAS COVERED: The authors review the most recent pharmacological and non-pharmacological randomized clinical trials (RCTs), focusing on the molecules involved, mechanisms of action, and pharmacological testing.
- The present review article is based on multiple database searches (MEDLINE, EMBASE, Scopus, Ovid, and Google Scholar) on all the available literature up to the 1 May 2025.
- EXPERT OPINION: Ongoing RCTs aimed to evaluate new disease-modifying or symptomatic treatment for FTD and to determine whether therapeutic strategies should target specific genetic mutations or focus on common protein deposits in the brain.
- These studies are laying the groundwork for future innovations.
- This shift could enable the transition from treating genetic FTD to tackling sporadic cases as well.
Why it matters
No disease-modifying therapy currently exists for frontotemporal dementia, and compounds developed so far have been designed to target specific genetic mutations. Ongoing randomized clinical trials are evaluating new disease-modifying or symptomatic treatments and whether strategies should target specific mutations or common protein deposits, but these are still laying groundwork for future innovations.
Study details
- Evidence strengthHigh
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Expert Review of Neurotherapeutics) |
| Journal's citation record | 1 / 4 | Expert Review of Neurotherapeutics: journal h-index 125 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 2 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 2 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Francesco Panza: h-index 92 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Amsterdam: institution h-index 1,209 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 8 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40804782) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 20.
Related studies in Lewy body dementia from nearby years
Also tagged “lewy”
1,017 studies in the library carry the topic tag “lewy”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,017 tagged studies.